share_log

HC Wainwright & Co. Maintains Buy on TCR2 Therapeutics, Lowers Price Target to $13

HC Wainwright & Co. Maintains Buy on TCR2 Therapeutics, Lowers Price Target to $13

HC Wainwright&Co.继续买入TCR2治疗公司,将目标价下调至13美元
Benzinga Real-time News ·  2022/11/21 06:42

HC Wainwright & Co. analyst Robert Burns maintains TCR2 Therapeutics (NASDAQ:TCRR) with a Buy and lowers the price target from $14 to $13.

HC Wainwright&Co.分析师罗伯特·伯恩斯维持TCR2治疗公司(纳斯达克:TCRR)的买入,并将目标价从14美元下调至13美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发